PMID- 32316976
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20231113
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Print)
IS  - 1465-9921 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Apr 21
TI  - Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD 
      in idiopathic pulmonary fibrosis.
PG  - 91
LID - 10.1186/s12931-020-01359-3 [doi]
LID - 91
AB  - BACKGROUND: Idiopathic pulmonary fibrosis (IPF) specific version of St. George's 
      Respiratory Questionnaire (SGRQ-I) and King's Brief Interstitial Lung Disease 
      questionnaire (K-BILD) are validated health-related quality of life (HRQL) 
      instruments, but no or limited data exist on their responsiveness and minimal 
      clinically important difference (MCID). The objectives of this study were to 
      assess responsiveness of SGRQ-I and K-BILD and determine MCID separately for 
      deterioration and improvement in a large, prospective cohort of patients with IPF 
      in a real-world setting. METHODS: Consecutive patients with IPF were recruited. 
      SGRQ-I, K-BILD, SGRQ, Shortness of Breath Questionnaire, pulmonary function tests 
      and 6-min walk test measurements were obtained at baseline and at six and 
      12 months; at six and 12 months, patients also completed Global Rating of Change 
      Scales. Responsiveness was assessed using correlation coefficients and linear 
      regression. Cox regression was used for mortality analyses. MCID was estimated 
      using receiver operating characteristic curves with separate analyses for 
      improvement and deterioration. RESULTS: A total of 150 IPF patients were included 
      and 124 completed the 12-month follow-up. Based on all HRQL anchors and most 
      physiological anchors, responsiveness analyses supported the evidence pointing 
      towards SGRQ-I and K-BILD as responsive instruments. Multivariate analyses showed 
      an association between SGRQ-I and mortality (HR: 1.18, 95% CI: 1.02 to 1.36, 
      p = 0.03) and a trend was found for K-BILD (HR: 0.82, 95% CI: 0.64 to 1.05, 
      p = 0.12). MCID was estimated for all domains of SGRQ-I and K-BILD. MCID for 
      improvement differed from deterioration for both SGRQ-I Total (3.9 and 4.9) and 
      K-BILD Total (4.7 and 2.7). CONCLUSIONS: SGRQ-I and K-BILD were responsive to 
      change concerning both HRQL and most physiological anchors. MCID was determined 
      separately for improvement and deterioration, resulting in different estimates; 
      especially a smaller estimate for deterioration compared to improvement in 
      K-BILD. TRIAL REGISTRATION: Clinicaltrials.gov, no. NCT02818712. Registered 30 
      June 2016.
FAU - Prior, Thomas Skovhus
AU  - Prior TS
AD  - Center for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, 
      Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200, Aarhus N, 
      Denmark. thbjer@rm.dk.
FAU - Hoyer, Nils
AU  - Hoyer N
AD  - Department of Respiratory Medicine, Herlev and Gentofte Hospital, Copenhagen, 
      Denmark.
FAU - Hilberg, Ole
AU  - Hilberg O
AD  - Department of Respiratory Medicine, Vejle Hospital, Vejle, Denmark.
FAU - Shaker, Saher Burhan
AU  - Shaker SB
AD  - Department of Respiratory Medicine, Herlev and Gentofte Hospital, Copenhagen, 
      Denmark.
FAU - Davidsen, Jesper Romhild
AU  - Davidsen JR
AD  - Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark.
FAU - Bendstrup, Elisabeth
AU  - Bendstrup E
AD  - Center for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, 
      Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200, Aarhus N, 
      Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT02818712
GR  - 118860/TrygFonden/
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200421
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
SB  - IM
MH  - Aged
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Idiopathic Pulmonary Fibrosis/*diagnosis/*psychology/therapy
MH  - Lung Diseases, Interstitial/*diagnosis/*psychology/therapy
MH  - Male
MH  - Middle Aged
MH  - *Minimal Clinically Important Difference
MH  - Prospective Studies
MH  - Quality of Life/*psychology
MH  - Treatment Outcome
MH  - Walk Test/methods/psychology
PMC - PMC7175493
OTO - NOTNLM
OT  - Health-related quality of life
OT  - IPF
OT  - IPF-specific version of St. Georges respiratory questionnaire
OT  - Idiopathic pulmonary fibrosis
OT  - K-BILD
OT  - King's Brief Interstitial Lung Disease questionnaire
OT  - Longitudinal validity
OT  - Responsiveness
OT  - SGRQ-I
OT  - minimal clinically important difference
COIS- OH, EB and TSP have received an unrestricted grant from Boehringer Ingelheim for 
      the current work. Outside the current work, TSP, JRD and EB have received fees 
      from Roche and Boehringer Ingelheim. SBS and NH declare no competing interests.
EDAT- 2020/04/23 06:00
MHDA- 2021/03/11 06:00
PMCR- 2020/04/21
CRDT- 2020/04/23 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/04/12 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
PHST- 2020/04/21 00:00 [pmc-release]
AID - 10.1186/s12931-020-01359-3 [pii]
AID - 1359 [pii]
AID - 10.1186/s12931-020-01359-3 [doi]
PST - epublish
SO  - Respir Res. 2020 Apr 21;21(1):91. doi: 10.1186/s12931-020-01359-3.